AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Pharm Country

Pharm Country Hotbed Continues to Prove it is Home to a Hot Job Market

BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.

July 9, 2021

5 min read

Mark Terry

BioForest

Clinical Catch-Up: June 28-July 2

It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.

July 2, 2021

13 min read

Mark Terry

SKYRIZI is the new option for psoriatic arthritis.

Drug Development

AbbVie’s Rinvoq Shows Promise as Maintenance Drug for Ulcerative Colitis Treatment

Rinvoq shows promising results for Ulcerative Colitis Treatment. The company said more patients treated with Rinvoq in the 52-week study achieved clinical remission compared to placebo.

June 29, 2021

3 min read

Alex Keown

Courtesy of Smith Collection/Gado/Getty Images

Drug Development

With Myeloma Drug Proving Merit in Phase I, AbbVie Scoops Up TeneoOne

The decision to exercise the option was based on an interim analysis of the ongoing Phase I trial of TNB-383B.

June 24, 2021

2 min read

Mark Terry

Photo courtesy of Capsida Biotherapeutics Inc.

Business

CRISPR and Capsida Partner in Gene Edited Therapies for ALS, Friedreich’s Ataxia

Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.

June 14, 2021

3 min read

Heather McKenzie

Business

AbbVie Partners With Caraway to Develop Parkinson’s Disease Therapeutics

The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.

June 9, 2021

3 min read

Brandon May

Business

Kojin Therapeutics Debuts to Solve Difficult Diseases Through Cell Behavior

Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.

June 9, 2021

3 min read

Mark Terry

Policy

Pharma on Trial: Multiple Companies are in Legal Crosshairs

AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.

June 3, 2021

3 min read

Alex Keown

Drug Development

Migraines Be Gone: AbbVie’s Atogepant Reduces Headache Frequency and Severity

Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie. So migraines will be gone sooner than we think.

June 3, 2021

4 min read

Gail Dutton

JOBS